Waqas Khatri
Founder and Chief Investment Officer
Ayrton was founded by Waqas Khatri in December 2016 after a successful investment career at Oasis Capital Management and Tenor Capital Management where he ran portfolios active in private placements, convertible arbitrage, volatility arbitrage, event-driven/distressed and risk arbitrage. Prior to that, Mr. Khatri was a Vice President at JPMorgan Asset Management responsible for selection of investment managers deploying relative value strategies. Mr. Khatri graduated from Vassar College, New York in 2002 with a BA in Computer Science and Economics. He is a founding board member of the Karen Leung Foundation, a charitable organization with a mission is to save lives by reducing the impact of gynaecological cancers in Hong Kong.
Marian Freidin
Operations Manager
Marian Freidin joined Ayrton in August 2017 and serves as its Operations Manager, responsible for the firm’s fund accounting, tax, treasury and trade operations. Prior to joining Ayrton, Ms. Freidin was a client service analyst with the Prime Brokerage division at Maxim Group LLC where she supported client integration with Maxim’s trade, finance and compliance infrastructure. Ms. Freidin holds degrees in Business Management and Equine Science from Colorado State.
Eric Arinsburg
Managing Director
Eric Arinsburg joined Ayrton in January 2021 as a Portfolio Manager responsible for convertible arbitrage. Mr. Arinsburg was previously a Managing Director at CNH Partners (the arbitrage affiliate of AQR Capital) responsible for over $5 billion of assets. Additionally, he is a co-founder of CNH Finance, an asset-backed lender focusing on healthcare loans, and Source Identity, a software company specializing in data collection in the aerospace and defense supply chain. Mr. Arinsburg has a BS in Applied Economics and Management from Cornell University and an MBA from the Wharton School of the University of Pennsylvania.
Samar Hamza
Research Analyst
Samar Hamza joined Ayrton in August 2018 and acts as the firm’s research analyst, covering the biotechnology, specialty pharmaceutical and medical device sectors. Ms. Hamza was previously a clinical researcher at UC San Diego assisting with clinical study design, implementation and data analysis. Some of her research work included neurodegeneration and neuro-imaging. Ms. Hamza was also a research consultant with Mark Kreuger & Associates, a leading patient engagement and advocacy consulting firm to the biopharmaceutical industry. She holds a Masters in Public Health with a concentration in Epidemiology and Statistics from Columbia University and a BS in Biology from University of California, San Diego.
Jarryd Gross
Research Analyst
Jarryd Gross joined Ayrton in April 2021 and acts as a research analyst for the firm. Prior to joining Ayrton, Mr. Gross served as an Equity Capital Markets Associate at H.C. Wainwright & Co., where he focused on the structuring and execution of numerous capital raises for small and micro cap companies across multiple sectors. Mr. Gross has also held ECM positions with Robert W. Baird and Baader Helvea AG. He holds dual bachelor degrees in Commerce and Economics, with majors in Finance, Accounting and Economics from the University of New South Wales, Sydney Australia